Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors

Current Pharmaceutical Biotechnology

Volumn 14, Issue 3, 2013, Pages 357-376

  Hahn, T ^a   Polanczyk, M J ^a   Borodovsky, A ^a   Ramanathapuram, L V ^a   Akporiaye, E T ^a   Ralph, S J ^b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cancer therapy; Immunotherapy; Inflammasome; Mitocans; Mitochondria; Reactive oxygen species

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTIMYCIN A1; ARSENIC TRIOXIDE; ARSENOUS ACID DERIVATIVE; BETULIC ACID; CASPASE 9; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CRYOPYRIN; DEOXYGLUCOSE; GOSSYPOL; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 18; ISOTHIOCYANIC ACID DERIVATIVE; LONIDAMINE; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; RESVERATROL; RHODAMINE 123; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL DEATH; CELLULAR IMMUNITY; CHRONIC GRANULOMATOUS DISEASE; DNA DAMAGE; DNA DEGRADATION; DNA FRAGMENTATION; HUMAN; IMMUNOGENICITY; NONHUMAN;

ANTINEOPLASTIC AGENTS; CELL DEATH; IMMUNOTHERAPY; INFLAMMASOMES; NEOPLASMS; REACTIVE OXYGEN SPECIES; VITAMIN E;

EID: 84875358306     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201011314030010     Document Type: Article

References (164)

1. Srikrishna, G.; Freeze, H. H. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia., 2009, 11 (7), 615-628.
2. Duprez, L.; Wirawan, E.; Vanden Berghe, T.; Vandenabeele, P. Major cell death pathways at a glance. Microbes Infect., 2009, 11 (13), 1050-1062.
3. Fink, S. L.; Cookson, B. T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun., 2005, 73 (4), 1907-1916.
4. Kepp, O.; Tesniere, A.; Zitvogel, L.; Kroemer, G. The immunogenicity of tumor cell death. Curr. Opin. Oncol., 2009, 21 (1), 71-76.
5. Kepp, O.; Tesniere, A.; Schlemmer, F.; Michaud, M.; Senovilla, L.; Zitvogel, L.; Kroemer, G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis, 2009, 14 (4), 364-375.
6. Fulda, S.; Gorman, A. M.; Hori, O.; Samali, A. Cellular stress responses: cell survival and cell death. Int. J. Cell Biol., 2010, 2010, 214074.
7. Walker, N. I.; Harmon, B. V.; Gobe, G. C.; Kerr, J. F. Patterns of cell death. Methods Achiev. Exp. Pathol., 1988, 13, 18-54.
8. Bergsbaken, T.; Fink, S. L.; Cookson, B. T. Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol., 2009, 7 (2), 99-9109.
9. Ghiringhelli, F.; Apetoh, L.; Tesniere, A.; Aymeric, L.; Ma, Y.; Ortiz, C.; Vermaelen, K.; Panaretakis, T.; Mignot, G.; Ullrich, E.; Perfettini, J. L.; Schlemmer, F.; Tasdemir, E.; Uhl, M.; Genin, P.; Civas, A.; Ryffel, B.; Kanellopoulos, J.; Tschopp, J.; Andre, F.; Lidereau, R.; McLaughlin, N. M.; Haynes, N. M.; Smyth, M. J.; Kroemer, G.; Zitvogel, L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med., 2009, 15 (10), 1170-1178.
10. Schroder, K.; Tschopp, J. The inflammasomes. Cell 2010, 140 (6), 821-832.
11. Latz, E. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol., 2010, 22 (1), 28-33.
12. Martinon, F.; Mayor, A.; Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol., 2009, 27, 229-265.
13. Bao, Q.; Shi, Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ., 2007, 14 (1), 56-65.
14. Teng, X.; Hardwick, J. M. The apoptosome at high resolution. Cell, 2010, 141 (3), 402-404.
15. Mariathasan, S.; Newton, K.; Monack, D. M.; Vucic, D.; French, D. M.; Lee, W. P.; Roose-Girma, M.; Erickson, S.; Dixit, V. M. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature, 2004, 430 (6996), 213-218.
16. Shaw, P. J.; Lamkanfi, M.; Kanneganti, T. D. NOD-like receptor (NLR) signaling beyond the inflammasome. Eur. J. Immunol., 2010, 40 (3), 624-627.
17. Lamkanfi, M.; Dixit, V. M. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev., 2009, 227 (1), 95-9105.
18. Pedra, J. H. F.; Cassel, S. L.; Sutterwala, F. S. Sensing pathogens and danger signals by the inflammasome. Curr. Opin. Immunol., 2009, 21 (1), 10-16.
19. Martins, I.; Tesniere, A.; Kepp, O.; Michaud, M.; Schlemmer, F.; Senovilla, L.; Seror, C.; Metivier, D.; Perfettini, J. L.; Zitvogel, L.; Kroemer, G. Chemotherapy induces ATP release from tumor cells. Cell Cycle, 2009, 8 (22), 3723-3728.
20. Kabakov, A. E.; Gabai, V. L. Heat shock-induced accumulation of 70-kDa stress protein (HSP70) can protect ATP-depleted tumor cells from necrosis. Exp. Cell Res., 1995, 217 (1), 15-21.
21. Leist, M.; Single, B.; Castoldi, A. F.; Kuhnle, S.; Nicotera, P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med., 1997, 185 (8), 1481-1486.
22. Leist, M.; Single, B.; Naumann, H.; Fava, E.; Simon, B.; Kuhnle, S.; Nicotera, P. Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp. Cell Res., 1999, 249 (2), 396-403.
23. Tsujimoto, Y.; Shimizu, S.; Eguchi, Y.; Kamiike, W.; Matsuda, H. Bcl-2 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways. Leukemia 1997, 11 (Suppl) 3, 380-382.
24. Aymeric, L.; Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Martins, I.; Kroemer, G.; Smyth, M. J.; Zitvogel, L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res., 2010, 70 (3), 855-858.
25. Kaufmann, A.; Musset, B.; Limberg, S. H.; Renigunta, V.; Sus, R.; Dalpke, A. H.; Heeg, K. M.; Robaye, B.; Hanley, P. J. Host tissue damage signal ATP promotes non-directional migration and negatively regulates toll-like receptor signaling in human monocytes. J. Biol. Chem., 2005, 280 (37), 32459-32467.
26. Hanley, P. J.; Musset, B.; Renigunta, V.; Limberg, S. H.; Dalpke, A. H.; Sus, R.; Heeg, K. M.; Preisig-Muller, R.; Daut, J. Extracellular ATP induces oscillations of intracellular Ca2+ and membrane potential and promotes transcription of IL-6 in macrophages. Proc. Natl. Acad. Sci. USA, 2004, 101 (25), 9479-9484.
27. Elliott, M. R.; Chekeni, F. B.; Trampont, P. C.; Lazarowski, E. R.; Kadl, A.; Walk, S. F.; Park, D.; Woodson, R. I.; Ostankovich, M.; Sharma, P.; Lysiak, J. J.; Harden, T. K.; Leitinger, N.; Ravichandran, K. S. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature, 2009, 461 (7261), 282-286.
28. Hornung, V.; Latz, E. Intracellular DNA recognition. Nat. Rev. Immunol., 2010, 10 (2), 123-130.
29. Lippmann, J.; Rothenburg, S.; Deigendesch, N.; Eitel, J.; Meixenberger, K.; van Laak, V.; Slevogt, H.; N'guessan, P. D.; Hippenstiel, S.; Chakraborty, T.; Flieger, A.; Suttorp, N.; Opitz, B. IFNbeta responses induced by intracellular bacteria or cytosolic DNA in different human cells do not require ZBP1 (DLM-1/DAI). Cell Microbiol., 2008, 10 (12), 2579-2588.
30. Takaoka, A.; Wang, Z.; Choi, M. K.; Yanai, H.; Negishi, H.; Ban, T.; Lu, Y.; Miyagishi, M.; Kodama, T.; Honda, K.; Ohba, Y.; Taniguchi, T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature, 2007, 448 (7152), 501-505.
31. Fernandes-Alnemri, T.; Yu, J. W.; Datta, P.; Wu, J.; Alnemri, E. S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature, 2009, 458 (7237), 509-513.
32. Hornung, V.; Ablasser, A.; Charrel-Dennis, M.; Bauernfeind, F.; Horvath, G.; Caffrey, D. R.; Latz, E.; Fitzgerald, K. A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature, 2009, 458 (7237), 514-518.
33. Schroder, K.; Muruve, D. A.; Tschopp, J. Innate immunity: cytoplasmic DNA sensing by the AIM2 inflammasome. Curr. Biol., 2009, 19 (6), 262-265.
34. Ishii, K. J.; Kawagoe, T.; Koyama, S.; Matsui, K.; Kumar, H.; Kawai, T.; Uematsu, S.; Takeuchi, O.; Takeshita, F.; Coban, C.; Akira, S. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature, 2008, 451 (7179), 725-729.
35. Kaiser, W. J.; Upton, J. W.; Mocarski, E. S. Receptor-interacting protein homotypic interaction motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN regulatory factors. J. Immunol., 2008, 181 (9), 6427-6434.
36. Rebsamen, M.; Heinz, L. X.; Meylan, E.; Michallet, M. C.; Schroder, K.; Hofmann, K.; Vazquez, J.; Benedict, C. A.; Tschopp, J. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep., 2009, 10 (8), 916-922.
37. Ablasser, A.; Bauernfeind, F.; Hartmann, G.; Latz, E.; Fitzgerald, K. A.; Hornung, V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol., 2009, 10 (10), 1065-1072.
38. Chiu, Y. H.; Macmillan, J. B.; Chen, Z. J. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell, 2009, 138 (3), 576-591.
39. Choi, M. K.; Wang, Z.; Ban, T.; Yanai, H.; Lu, Y.; Koshiba, R.; Nakaima, Y.; Hangai, S.; Savitsky, D.; Nakasato, M.; Negishi, H.; Takeuchi, O.; Honda, K.; Akira, S.; Tamura, T.; Taniguchi, T. A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA. Proc. Natl. Acad Sci. USA, 2009, 106 (42), 17870-17875.
40. Yoneyama, M.; Fujita, T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol. Rev., 2009, 227 (1), 54-65.
41. Bricio, T.; Molina, A.; Martin, A.; Mampaso, F. In vitro modulation of interleukin-1 beta secretion by cultured rat doxorubicin-stimulated whole glomeruli and dissociated mesangial glomerular cells. Immunology, 1994, 81 (1), 53-57.
42. Childs, A. C.; Phaneuf, S. L.; Dirks, A. J.; Phillips, T.; Leeuwenburgh, C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res., 2002, 62 (16), 4592-4598.
43. Thalappilly, S.; Sadasivam, S.; Radha, V.; Swarup, G. Involvement of caspase 1 and its activator Ipaf upstream of mitochondrial events in apoptosis. FEBS J., 2006, 273 (12), 2766-2778.
44. Burckstummer, T.; Baumann, C.; Bluml, S.; Dixit, E.; Durnberger, G.; Jahn, H.; Planyavsky, M.; Bilban, M.; Colinge, J.; Bennett, K. L.; Superti-Furga, G. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat. Immunol., 2009, 10 (3), 266-272.
45. Roberts, T. L.; Idris, A.; Dunn, J. A.; Kelly, G. M.; Burnton, C. M.; Hodgson, S.; Hardy, L. L.; Garceau, V.; Sweet, M. J.; Ross, I. L.; Hume, D. A.; Stacey, K. J. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science, 2009, 323 (5917), 1057-1060.
46. Rathinam, V. A. K.; Jiang, Z.; Waggoner, S. N.; Sharma, S.; Cole, L. E.; Waggoner, L.; Vanaja, S. K.; Monks, B. G.; Ganesan, S.; Latz, E.; Hornung, V.; Vogel, S. N.; Szomolanyi-Tsuda, E.; Fitzgerald, K. A. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat, Immunol., 2010, 11 (5), 395-402.
47. Muruve, D. A.; Petrilli, V.; Zaiss, A. K.; White, L. R.; Clark, S. A.; Ross, P. J.; Parks, R. J.; Tschopp, J. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature, 2008, 452 (7183), 103-107.
48. Yanai, H.; Ban, T.; Wang, Z.; Choi, M. K.; Kawamura, T.; Negishi, H.; Nakasato, M.; Lu, Y.; Hangai, S.; Koshiba, R.; Savitsky, D.; Ronfani, L.; Akira, S.; Bianchi, M. E.; Honda, K.; Tamura, T.; Kodama, T.; Taniguchi, T. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature, 2009, 462 (7269), 99-9103.
49. Sims, G. P.; Rowe, D. C.; Rietdijk, S. T.; Herbst, R.; Coyle, A. J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol., 2010, 28, 367-388.
50. Martinon, F. Signaling by ROS drives inflammasome activation. Eur J. Immunol., 2010, 40 (3), 616-619.
51. Tschopp, J.; Schroder, K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol., 2010, 10 (3), 210-215.
52. Dostert, C.; Petrilli, V.; Van Bruggen, R.; Steele, C.; Mossman, B. T.; Tschopp, J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science, 2008, 320 (5876), 674-677.
53. van de Veerdonk, F. L.; Smeekens, S. P.; Joosten, L. A. B.; Kullberg, B. J.; Dinarello, C. A.; van der Meer, J. W. M.; Netea, M. G. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc. Natl. Acad Sci. USA, 2010, 107 (7), 3030-3033.
54. van, B. R.; Koker, M. Y.; Jansen, M.; van, H. M.; Roos, D.; Kuijpers, T. W.; van den Berg, T. K. Human NLRP3 inflammasome activation is Nox1-4 independent. Blood, 2010, 115 (26), 5398-5400.
55. Emmendorffer, A.; Roesler, J.; Elsner, J.; Raeder, E.; Lohmann-Matthes, M. L.; Meier, B. Production of oxygen radicals by fibroblasts and neutrophils from a patient with x-linked chronic granulomatous disease. Eur. J. Haematol., 1993, 51 (4), 223-227.
56. Hu, S.; Zhao, H.; Yin, X. J.; Ma, J. K. H. Role of mitochondria in silica-induced apoptosis of alveolar macrophages: inhibition of apoptosis by rhodamine 6G and N-acetyl-L-cysteine. J. Toxicol. Environ. Health A., 2007, 70 (17), 1403-1415.
57. Cruz, C. M.; Rinna, A.; Forman, H. J.; Ventura, A. L. M.; Persechini, P. M.; Ojcius, D. M. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J. Biol. Chem., 2007, 282 (5), 2871-2879.
58. Franchi, L.; Eigenbrod, T.; Nunez, G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J. Immunol., 2009, 183 (2), 792-796.
59. Bowie, A.; O'Neill, L. A. Oxidative stress and nuclear factorkappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol., 2000, 59 (1), 13-23.
60. Haddad, J. J. Redox regulation of pro-inflammatory cytokines and IkappaB-alpha/NF-kappaB nuclear translocation and activation. Biochem. Biophys. Res. Commun., 2002, 296 (4), 847-856.
61. Hwang, Y. S.; Jeong, M.; Park, J. S.; Kim, M. H.; Lee, D. B.; Shin, B. A.; Mukaida, N.; Ellis, L. M.; Kim, H. R.; Ahn, B. W.; Jung, Y. D. Interleukin-1beta stimulates IL-8 expression through MAP kinase and ROS signaling in human gastric carcinoma cells. Oncogene, 2004, 23 (39), 6603-6611.
62. Woo, C. H.; Eom, Y. W.; Yoo, M. H.; You, H. J.; Han, H. J.; Song, W. K.; Yoo, Y. J.; Chun, J. S.; Kim, J. H. Tumor necrosis factoralpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J. Biol. Chem., 2000, 275 (41), 32357-32362.
63. Pfeiffer, Z. A.; Guerra, A. N.; Hill, L. M.; Gavala, M. L.; Prabhu, U.; Aga, M.; Hall, D. J.; Bertics, P. J. Nucleotide receptor signaling in murine macrophages is linked to reactive oxygen species generation. Free Radic. Biol. Med., 2007, 42 (10), 1506-1516.
64. Ferrari, D.; Pizzirani, C.; Adinolfi, E.; Lemoli, R. M.; Curti, A.; Idzko, M.; Panther, E.; Di Virgilio, F. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol., 2006, 176 (7), 3877-3883.
65. Hancock, J. T. The role of redox mechanisms in cell signalling. Mol. Biotechnol., 2009, 43 (2), 162-166.
66. Rhee, S. G. Cell signaling. H2O2, a necessary evil for cell signaling. Science, 2006, 312 (5782), 1882-1883.
67. Janssen-Heininger, Y. M. W.; Mossman, B. T.; Heintz, N. H.; Forman, H. J.; Kalyanaraman, B.; Finkel, T.; Stamler, J. S.; Rhee, S. G.; van der Vliet, A. Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic. Biol. Med., 2008, 45 (1), 1-17.
68. Murphy, M. P. Mitochondria--a neglected drug target. Curr. Opin. Investig Drugs, 2009, 10 (10), 1022-1024.
69. Zhou, R.; Tardivel, A.; Thorens, B.; Choi, I.; Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol., 2010, 11 (2), 136-140.
70. Tattoli, I.; Carneiro, L. A.; Jehanno, M.; Magalhaes, J. G.; Shu, Y.; Philpott, D. J.; Arnoult, D.; Girardin, S. E. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production. EMBO Rep., 2008, 9 (3), 293-300.
71. Arnoult, D.; Soares, F.; Tattoli, I.; Castanier, C.; Philpott, D. J.; Girardin, S. E. An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. J. Cell Sci., 2009, 122 (Pt 17), 3161-3168.
72. Moore, C. B.; Bergstralh, D. T.; Duncan, J. A.; Lei, Y.; Morrison, T. E.; Zimmermann, A. G.; Accavitti-Loper, M. A.; Madden, V. J.; Sun, L.; Ye, Z.; Lich, J. D.; Heise, M. T.; Chen, Z.; Ting, J. P. Y. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature, 2008, 451 (7178), 573-577.
73. Gertz, M.; Steegborn, C. The Lifespan-Regulator p66Shc in Mitochondria: Redox Enzyme or Redox Sensor? Antioxid Redox. Signal., 2010.
74. Tal, M. C.; Sasai, M.; Lee, H. K.; Yordy, B.; Shadel, G. S.; Iwasaki, A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc. Natl. Acad Sci. USA, 2009, 106 (8), 2770-2775.
75. Scott, I.; Norris, K. L. The mitochondrial antiviral signaling protein, MAVS, is cleaved during apoptosis. Biochem. Biophys. Res. Commun., 2008, 375 (1), 101-106.
76. Lei, Y.; Moore, C. B.; Liesman, R. M.; O'Connor, B. P.; Bergstralh, D. T.; Chen, Z. J.; Pickles, R. J.; Ting, J. P. Y. MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS One, 2009, 4 (5), e5466.
77. Yu, C. Y.; Chiang, R. L.; Chang, T. H.; Liao, C. L.; Lin, Y. L. The interferon stimulator mitochondrial antiviral signaling protein facilitates cell death by disrupting the mitochondrial membrane potential and by activating caspases. J. Virol., 2010, 84 (5), 2421-2431.
78. Neuzil, J.; Tomasetti, M.; Zhao, Y.; Dong, L. F.; Birringer, M.; Wang, X. F.; Low, P.; Wu, K.; Salvatore, B. A.; Ralph, S. J. Vitamin E analogs, a novel group of mitocans, as anticancer agents: the importance of being redox-silent. Mol. Pharmacol., 2007, 71 (5), 1185-1199.
79. Neuzil, J.; Dong, L. F.; Ramanathapuram, L.; Hahn, T.; Chladova, M.; Wang, X. F.; Zobalova, R.; Prochazka, L.; Gold, M.; Freeman, R.; Turanek, J.; Akporiaye, E. T.; Dyason, J. C.; Ralph, S. J. Vitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondria. Mol. Aspects Med., 2007, 28 (5-6), 607-645.
80. Weber, T.; Dalen, H.; Andera, L.; Negre-Salvayre, A.; Auge, N.; Sticha, M.; Lloret, A.; Terman, A.; Witting, P. K.; Higuchi, M.; Plasilova, M.; Zivny, J.; Gellert, N.; Weber, C.; Neuzil, J. Mitochondria play a central role in apoptosis induced by alphatocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. Biochemistry, 2003, 42 (14), 4277-4291.
81. Hileman, E. O.; Liu, J.; Albitar, M.; Keating, M. J.; Huang, P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol., 2004, 53 (3), 209-219.
82. Wang, X. F.; Dong, L.; Zhao, Y.; Tomasetti, M.; Wu, K.; Neuzil, J. Vitamin E analogues as anticancer agents: lessons from studies with alpha-tocopheryl succinate. Mol. Nutr. Food Res., 2006, 50 (8), 675-685.
83. Kogure, K.; Hama, S.; Manabe, S.; Tokumura, A.; Fukuzawa, K. High cytotoxicity of alpha-tocopheryl hemisuccinate to cancer cells is due to failure of their antioxidative defense systems. Cancer Lett., 2002, 186 (2), 151-156.
84. Wang, X. F.; Witting, P. K.; Salvatore, B. A.; Neuzil, J. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem. Biophys. Res. Commun., 2005, 326 (2), 282-289.
85. Kelso, G. F.; Porteous, C. M.; Coulter, C. V.; Hughes, G.; Porteous, W. K.; Ledgerwood, E. C.; Smith, R. A.; Murphy, M. P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem., 2001, 276 (7), 4588-4596.
86. Alleva, R.; Tomasetti, M.; Andera, L.; Gellert, N.; Borghi, B.; Weber, C.; Murphy, M. P.; Neuzil, J. Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Lett., 2001, 503 (1), 46-50.
87. Kang, Y. H.; Lee, E.; Choi, M. K.; Ku, J. L.; Kim, S. H.; Park, Y. G.; Lim, S. J. Role of reactive oxygen species in the induction of apoptosis by alpha-tocopheryl succinate. Int. J. Cancer, 2004, 112 (3), 385-392.
88. Dong, L. F.; Swettenham, E.; Eliasson, J.; Wang, X. F.; Gold, M.; Medunic, Y.; Stantic, M.; Low, P.; Prochazka, L.; Witting, P. K.; Turanek, J.; Akporiaye, E. T.; Ralph, S. J.; Neuzil, J. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res., 2007, 67 (24), 11906-11913.
89. Dong, L. F.; Freeman, R.; Liu, J.; Zobalova, R.; Marin-Hernandez, A.; Stantic, M.; Rohlena, J.; Valis, K.; Rodriguez-Enriquez, S.; Butcher, B.; Goodwin, J.; Brunk, U. T.; Witting, P. K.; Moreno-Sanchez, R.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res., 2009, 15 (5), 1593-1600.
90. D'Alessio, M.; De, N. M.; Coppola, S.; Gualandi, G.; Pugliese, L.; Cerella, C.; Cristofanon, S.; Civitareale, P.; Ciriolo, M. R.; Bergamaschi, A.; Magrini, A.; Ghibelli, L. Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J., 2005, 19 (11), 1504-1506.
91. Dewson, G.; Kratina, T.; Czabotar, P.; Day, C. L.; Adams, J. M.; Kluck, R. M. Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. Mol. Cell, 2009, 36 (4), 696-703.
92. Nie, C.; Tian, C.; Zhao, L.; Petit, P. X.; Mehrpour, M.; Chen, Q. Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. J. Biol. Chem., 2008, 283 (22), 15359-15369.
93. Prochazka, L.; Dong, L. F.; Valis, K.; Freeman, R.; Ralph, S. J.; Turanek, J.; Neuzil, J. alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis, 2010, 15 (7), 782-794.
94. Shankaran, V.; Ikeda, H.; Bruce, A. T.; White, J. M.; Swanson, P. E.; Old, L. J.; Schreiber, R. D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410 (6832), 1107-1111.
95. Smyth, M. J.; Dunn, G. P.; Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol., 2006, 90, 1-50.
96. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 2004, 21 (2), 137-148.
97. Swann, J. B.; Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest., 2007, 117 (5), 1137-1146.
98. Gattinoni, L.; Powell, D. J.; Rosenberg, S. A.; Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol., 2006, 6 (5), 383-393.
99. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature, 1998, 392 (6673), 245-252.
100. Boczkowski, D.; Nair, S. K.; Nam, J. H.; Lyerly, H. K.; Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res., 2000, 60 (4), 1028-1034.
101. Smits, E. L. J. M.; Ponsaerts, P.; Berneman, Z. N.; Van Tendeloo, V. F. I. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist, 2008, 13 (8), 859-875.
102. Smyth, M. J.; Cretney, E.; Kershaw, M. H.; Hayakawa, Y. Cytokines in cancer immunity and immunotherapy. Immunol. Rev., 2004, 202, 275-293.
103. Cheuk, A. T. C.; Mufti, G. J.; Guinn, B. A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther., 2004, 11 (3), 215-226.
104. Sugamura, K.; Ishii, N.; Weinberg, A. D. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol., 2004, 4 (6), 420-431.
105. Schabowsky, R. H.; Madireddi, S.; Sharma, R.; Yolcu, E. S.; Shirwan, H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig Drugs, 2007, 8 (12), 1002-1008.
106. Hirano, F.; Kaneko, K.; Tamura, H.; Dong, H.; Wang, S.; Ichikawa, M.; Rietz, C.; Flies, D. B.; Lau, J. S.; Zhu, G.; Tamada, K.; Chen, L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res., 2005, 65 (3), 1089-1096.
107. Leach, D. R.; Krummel, M. F.; Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996, 271 (5256), 1734-1736.
108. Rosenberg, S. A.; Yang, J. C.; Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 2004, 10 (9), 909-915.
109. Bodey, B.; Bodey, B.; Siegel, S. E.; Kaiser, H. E. Immunocytochemical detection of MMP-3 and -10 expression in hepatocellular carcinomas. Anticancer Res., 2000, 20 (6B), 4585-4590.
110. Phan, G. Q.; Yang, J. C.; Sherry, R. M.; Hwu, P.; Topalian, S. L.; Schwartzentruber, D. J.; Restifo, N. P.; Haworth, L. R.; Seipp, C. A.; Freezer, L. J.; Morton, K. E.; Mavroukakis, S. A.; Duray, P. H.; Steinberg, S. M.; Allison, J. P.; Davis, T. A.; Rosenberg, S. A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad Sci. USA, 2003, 100 (14), 8372-8377.
111. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G. M.; Apetoh, L.; Perfettini, J. L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Metivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13 (1), 54-61.
112. Lake, R. A.; Robinson, B. W. S. Immunotherapy and chemotherapy-- a practical partnership. Nat. Rev. Cancer, 2005, 5 (5), 397-405.
113. Liu, J. Y.; Wu, Y.; Zhang, X. S.; Yang, J. L.; Li, H. L.; Mao, Y. Q.; Wang, Y.; Cheng, X.; Li, Y. Q.; Xia, J. C.; Masucci, M.; Zeng, Y. X. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol. Immunother., 2007, 56 (10), 1597-1604.
114. Apetoh, L.; Mignot, G.; Panaretakis, T.; Kroemer, G.; Zitvogel, L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol. Med., 2008, 14 (4), 141-151.
115. Zitvogel, L.; Kepp, O.; Senovilla, L.; Menger, L.; Chaput, N.; Kroemer, G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. 2010, 2010/04/28, 3100-3104.
116. Spisek, R.; Charalambous, A.; Mazumder, A.; Vesole, D. H.; Jagannath, S.; Dhodapkar, M. V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. 2007, 2007/02/15, 4839-4845.
117. North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. 1982, 1982/04/01, 1063-1074.
118. Lutsiak, M. E.; Semnani, R. T.; De Pascalis, R.; Kashmiri, S. V.; Schlom, J.; Sabzevari, H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. 2005, 2004/12/14, 2862-2868.
119. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. 2010, 2010/05/15, 447-464.
120. Deaglio, S.; Canella, D.; Baj, G.; Arnulfo, A.; Waxman, S.; Malavasi, F. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells, 2001, 2001/02/28, 227-235.
121. Thejass, P.; Kuttan, G. Augmentation of natural killer cell and antibody-dependent cellular cytotoxicity in BALB/c mice by sulforaphane, a naturally occurring isothiocyanate from broccoli through enhanced production of cytokines IL-2 and IFN-gamma. 2006, 2006/09/26, 443-457.
122. Robinson, E.; Rubin, D.; Mekori, T.; Segal, R.; Pollack, S. In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer. 1993, 1993/08/01, 209-212.
123. Rotstein, S.; Blomgren, H.; Petrini, B.; Wasserman, J.; von Stedingk, L. V. Influence of adjuvant tamoxifen on blood lymphocytes. 1988, 1988/09/01, 75-79.
124. Yang, Y.; Paik, J. H.; Cho, D.; Cho, J. A.; Kim, C. W. Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. 2008, 2008/03/11, 542-547.
125. Behjati, S.; Frank, M. H. The effects of tamoxifen on immunity. 2009, 2009/08/20, 3076-3080.
126. Nizar, S.; Copier, J.; Meyer, B.; Bodman-Smith, M.; Galustian, C.; Kumar, D.; Dalgleish, A. T-regulatory cell modulation: the future of cancer immunotherapy? 2009, 2009/04/23, 1697-1703.
127. Sharma, S.; Chopra, K.; Kulkarni, S. K.; Agrewala, J. N. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. 2007, 2006/12/21, 155-163.
128. Svajger, U.; Obermajer, N.; Jeras, M. Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation. 2010, 2009/12/17, 525-535.
129. Singh, N. P.; Hegde, V. L.; Hofseth, L. J.; Nagarkatti, M.; Nagarkatti, P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. 2007, 2007/09/18, 1508-1521.
130. Udenigwe, C. C.; Ramprasath, V. R.; Aluko, R. E.; Jones, P. J. Potential of resveratrol in anticancer and anti-inflammatory therapy. 2008, 2008/08/01, 445-454.
131. Anderson, K.; Simmons-Menchaca, M.; Lawson, K. A.; Atkinson, J.; Sanders, B. G.; Kline, K. Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E Succinate and vitamin E analogue, alpha-TEA. Cancer Res., 2004, 64 (12), 4263-4269.
132. Hahn, T.; Szabo, L.; Gold, M.; Ramanathapuram, L.; Hurley, L. H.; Akporiaye, E. T. Dietary administration of the proapoptotic vitamin E analogue alpha-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res., 2006, 66 (19), 9374-9378.
133. Hahn, T.; Fried, K.; Hurley, L. H.; Akporiaye, E. T. Orally active alpha-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Mol. Cancer Ther., 2009, 8 (6), 1570-1578.
134. Lawson, K. A.; Anderson, K.; Simmons-Menchaca, M.; Atkinson, J.; Sun, L.; Sanders, B. G.; Kline, K. Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp. Biol. Med. (Maywood), 2004, 229 (9), 954-963.
135. Lawson, K. A.; Anderson, K.; Snyder, R. M.; Simmons-Menchaca, M.; Atkinson, J.; Sun, L. Z.; Bandyopadhyay, A.; Knight, V.; Gilbert, B. E.; Sanders, B. G.; Kline, K. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother. Pharmacol., 2004, 54 (5), 421-431.
136. Malafa, M. P.; Fokum, F. D.; Mowlavi, A.; Abusief, M.; King, M. Vitamin E inhibits melanoma growth in mice. Surgery, 2002, 131 (1), 85-91.
137. Neuzil, J.; Weber, T.; Gellert, N.; Weber, C. Selective cancer cell killing by alpha-tocopheryl succinate. Br. J. Cancer, 2001, 84 (1), 87-89.
138. Ramanathapuram, L. V.; Hahn, T.; Graner, M. W.; Katsanis, E.; Akporiaye, E. T. Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunol. Immunother., 2006, 55 (2), 166-177.
139. Kogure, K.; Manabe, S.; Hama, S.; Tokumura, A.; Fukuzawa, K. Potentiation of anti-cancer effect by intravenous administration of vesiculated alpha-tocopheryl hemisuccinate on mouse melanoma in vivo. Cancer Lett., 2003, 192 (1), 19-24.
140. Ramanathapuram, L. V.; Kobie, J. J.; Bearss, D.; Payne, C. M.; Trevor, K. T.; Akporiaye, E. T. alpha-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells. Cancer Immunol. Immunother., 2004, 53 (7), 580-588.
141. Neuzil, J. Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity. Br. J. Cancer, 2003, 89 (10), 1822-1826.
142. Neuzil, J.; Tomasetti, M.; Mellick, A. S.; Alleva, R.; Salvatore, B. A.; Birringer, M.; Fariss, M. W. Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects. Curr. Cancer Drug Targets, 2004, 4 (4), 355-372.
143. Tomasetti, M.; Strafella, E.; Staffolani, S.; Santarelli, L.; Neuzil, J.; Guerrieri, R. alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate. Br. J. Cancer, 2010, 102 (8), 1224-1234.
144. Kline, K.; Yu, W.; Sanders, B. G. Vitamin E: mechanisms of action as tumor cell growth inhibitors. J. Nutr., 2001, 131 (1), 163.
145. Neuzil, J. Alpha-tocopheryl succinate epitomizes a compound with a shift in biological activity due to pro-vitamin-to-vitamin conversion. Biochem. Biophys. Res. Commun., 2002, 293 (5), 1309-1313.
146. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol., 2008, 8 (1), 59-73.
147. Ramanathapuram, L. V.; Hahn, T.; Dial, S. M.; Akporiaye, E. T. Chemo-immunotherapy of breast cancer using vesiculated alphatocopheryl succinate in combination with dendritic cell vaccination. Nutr. Cancer, 2005, 53 (2), 177-193.
148. Heufler, C.; Koch, F.; Stanzl, U.; Topar, G.; Wysocka, M.; Trinchieri, G.; Enk, A.; Steinman, R. M.; Romani, N.; Schuler, G. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur. J. Immunol., 1996, 26 (3), 659-668.
149. Kline, K.; Yu, W.; Sanders, B. G. Vitamin E and breast cancer. J. Nutr., 2004, 134 (12 Suppl), 3462.
150. Kline, K.; Lawson, K. A.; Yu, W.; Sanders, B. G. Vitamin E and cancer. Vitam. Horm., 2007, 76, 435-461.
151. Neuzil, J.; Dyason, J. C.; Freeman, R.; Dong, L. F.; Prochazka, L.; Wang, X. F.; Scheffler, I.; Ralph, S. J. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J. Bioenerg. Biomembr., 2007, 39 (1), 65-72.
152. Feng, H.; Zeng, Y.; Graner, M. W.; Katsanis, E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood, 2002, 100 (12), 4108-4115.
153. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol., 2002, 20, 395-425.
154. Basu, S.; Binder, R. J.; Suto, R.; Anderson, K. M.; Srivastava, P. K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol., 2000, 12 (11), 1539-1546.
155. Bethke, K.; Staib, F.; Distler, M.; Schmitt, U.; Jonuleit, H.; Enk, A. H.; Galle, P. R.; Heike, M. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J. Immunol., 2002, 169 (11), 6141-6148.
156. Flohe, S. B.; Bruggemann, J.; Lendemans, S.; Nikulina, M.; Meierhoff, G.; Flohe, S.; Kolb, H. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J. Immunol., 2003, 170 (5), 2340-2348.
157. Basu, S.; Srivastava, P. K. Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int. Immunol., 2003, 15 (9), 1053-1061.
158. Mosser, D. D.; Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. Oncogene, 2004, 23 (16), 2907-2918.
159. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M. C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F. J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J. P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med., 2007, 13 (9), 1050-1059.
160. Chu, Y.; Wang, L. X.; Yang, G.; Ross, H. J.; Urba, W. J.; Prell, R.; Jooss, K.; Xiong, S.; Hu, H. M. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J. Immunother., 2006, 29 (4), 367-380.
161. Basu, S.; Binder, R. J.; Ramalingam, T.; Srivastava, P. K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 2001, 14 (3), 303-313.
162. Livesey, K. M.; Tang, D.; Zeh, H. J.; Lotze, M. T. Autophagy inhibition in combination cancer treatment. Curr. Opin. Investig Drugs, 2009, 10 (12), 1269-1279.
163. Kazama, H.; Ricci, J. E.; Herndon, J. M.; Hoppe, G.; Green, D. R.; Ferguson, T. A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity, 2008, 29 (1), 21-32.
164. Scaffidi, P.; Misteli, T.; Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 2002, 418 (6894), 191-195.